US5714493A
(en)
*
|
1991-05-10 |
1998-02-03 |
Rhone-Poulenc Rorer Pharmaceuticals, Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
US6645969B1
(en)
*
|
1991-05-10 |
2003-11-11 |
Aventis Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
US5721237A
(en)
*
|
1991-05-10 |
1998-02-24 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
|
US5710158A
(en)
*
|
1991-05-10 |
1998-01-20 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
USRE37650E1
(en)
|
1991-05-10 |
2002-04-09 |
Aventis Pharmacetical Products, Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
US7772432B2
(en)
|
1991-09-19 |
2010-08-10 |
Astrazeneca Ab |
Amidobenzamide derivatives which are useful as cytokine inhibitors
|
US5792771A
(en)
*
|
1992-11-13 |
1998-08-11 |
Sugen, Inc. |
Quinazoline compounds and compositions thereof for the treatment of disease
|
US5763441A
(en)
*
|
1992-11-13 |
1998-06-09 |
Sugen, Inc. |
Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
|
US5712395A
(en)
*
|
1992-11-13 |
1998-01-27 |
Yissum Research Development Corp. |
Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
|
US5981569A
(en)
*
|
1992-11-13 |
1999-11-09 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
|
GB9323290D0
(en)
|
1992-12-10 |
1994-01-05 |
Zeneca Ltd |
Quinazoline derivatives
|
PH31122A
(en)
*
|
1993-03-31 |
1998-02-23 |
Eisai Co Ltd |
Nitrogen-containing fused-heterocycle compounds.
|
GB9314893D0
(en)
*
|
1993-07-19 |
1993-09-01 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9325217D0
(en)
*
|
1993-12-09 |
1994-02-09 |
Zeneca Ltd |
Pyrimidine derivatives
|
AU739382B2
(en)
*
|
1993-12-10 |
2001-10-11 |
Aventis Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
US5700823A
(en)
*
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
IL112248A0
(en)
*
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
US6524832B1
(en)
*
|
1994-02-04 |
2003-02-25 |
Arch Development Corporation |
DNA damaging agents in combination with tyrosine kinase inhibitors
|
EP0746554A1
(en)
*
|
1994-02-23 |
1996-12-11 |
Pfizer Inc. |
4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
|
WO1995024190A2
(en)
|
1994-03-07 |
1995-09-14 |
Sugen, Inc. |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
EP0682027B1
(de)
*
|
1994-05-03 |
1997-10-15 |
Novartis AG |
Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
|
PT783505E
(pt)
*
|
1994-09-29 |
2001-08-30 |
Novartis Ag |
Pirrolo¬2,3-d|pirimidinas e sua utilizacao
|
TW321649B
(uk)
*
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
GB9424233D0
(en)
*
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
EP0817775B1
(en)
|
1995-03-30 |
2001-09-12 |
Pfizer Inc. |
Quinazoline derivatives
|
AU778961B2
(en)
*
|
1995-03-30 |
2004-12-23 |
Osi Pharmaceuticals, Inc. |
Intermediates for the preparation of 4-(substituted phenylamino)quinazoline derivatives
|
ES2150113T3
(es)
*
|
1995-04-03 |
2000-11-16 |
Novartis Ag |
Derivados de pirazol y procedimientos para la preparacion de los mismos.
|
US5721277A
(en)
*
|
1995-04-21 |
1998-02-24 |
Sugen, Inc. |
Compounds and methods for inhibiting hyper-proliferative cell growth
|
GB9508565D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
GB9508538D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
AU5343096A
(en)
*
|
1995-04-27 |
1996-11-18 |
Zeneca Limited |
Quinazoline derivatives
|
GB9508535D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
GB9508537D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US5639757A
(en)
*
|
1995-05-23 |
1997-06-17 |
Pfizer Inc. |
4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
DE69618587T2
(de)
*
|
1995-06-07 |
2002-08-29 |
Sugen, Inc. |
Chinazoline und pharmazeutische zusammensetzungen
|
US6316635B1
(en)
|
1995-06-07 |
2001-11-13 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
US5763470A
(en)
*
|
1995-06-07 |
1998-06-09 |
Sugen Inc. |
Benzopyran compounds and methods for their use
|
US6147106A
(en)
|
1997-08-20 |
2000-11-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
US7119174B2
(en)
|
1995-12-18 |
2006-10-10 |
Sugen, Inc. |
Diagnosis and treatment of AUR1 and/or AUR2 related disorders
|
GB9624482D0
(en)
*
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
US6716575B2
(en)
|
1995-12-18 |
2004-04-06 |
Sugen, Inc. |
Diagnosis and treatment of AUR1 and/or AUR2 related disorders
|
ZA9756B
(en)
*
|
1996-01-16 |
1997-07-17 |
Warner Lambert Co |
Process for preparing 4,6-disubstituted pyrido[3,4-d]-pyrimidines
|
US5760041A
(en)
*
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
IL125686A
(en)
*
|
1996-02-13 |
2002-11-10 |
Zeneca Ltd |
Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
|
GB9603097D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
GB9603095D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
WO1997032856A1
(en)
*
|
1996-03-05 |
1997-09-12 |
Zeneca Limited |
4-anilinoquinazoline derivatives
|
DK0892789T4
(da)
|
1996-04-12 |
2010-04-06 |
Warner Lambert Co |
Irreversible inhibitorer af tyrosin kinaser
|
GB9607729D0
(en)
*
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
ID19609A
(id)
|
1996-07-13 |
1998-07-23 |
Glaxo Group Ltd |
Senyawa-senyawa heterosiklik
|
WO1998005661A1
(en)
*
|
1996-08-06 |
1998-02-12 |
Pfizer Inc. |
Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
|
WO1998010767A2
(en)
*
|
1996-09-13 |
1998-03-19 |
Sugen, Inc. |
Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
|
US6004967A
(en)
*
|
1996-09-13 |
1999-12-21 |
Sugen, Inc. |
Psoriasis treatment with quinazoline compounds
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
US6225318B1
(en)
|
1996-10-17 |
2001-05-01 |
Pfizer Inc |
4-aminoquinazolone derivatives
|
EP0837063A1
(en)
*
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
EP0946554A1
(en)
*
|
1996-11-27 |
1999-10-06 |
Pfizer Inc. |
Fused bicyclic pyrimidine derivatives
|
US6002008A
(en)
*
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
US6818440B2
(en)
|
1997-04-28 |
2004-11-16 |
Sugen, Inc. |
Diagnosis and treatment of alk-7 related disorders
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
US5929080A
(en)
*
|
1997-05-06 |
1999-07-27 |
American Cyanamid Company |
Method of treating polycystic kidney disease
|
US6316429B1
(en)
|
1997-05-07 |
2001-11-13 |
Sugen, Inc. |
Bicyclic protein kinase inhibitors
|
US6486185B1
(en)
|
1997-05-07 |
2002-11-26 |
Sugen, Inc. |
3-heteroarylidene-2-indolinone protein kinase inhibitors
|
US6316479B1
(en)
|
1997-05-19 |
2001-11-13 |
Sugen, Inc. |
Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
|
US6228641B1
(en)
|
1997-05-20 |
2001-05-08 |
Sugen, Inc. |
Diagnosis and treatment of PTP04 related disorders
|
US6987113B2
(en)
|
1997-06-11 |
2006-01-17 |
Sugen, Inc. |
Tyrosine kinase inhibitors
|
US6342593B1
(en)
|
1997-06-11 |
2002-01-29 |
Sugen, Inc. |
Diagnosis and treatment of ALP related disorders
|
US7115710B2
(en)
|
1997-06-11 |
2006-10-03 |
Sugen, Inc. |
Diagnosis and treatment of PTP related disorders
|
US6388063B1
(en)
|
1997-06-18 |
2002-05-14 |
Sugen, Inc. |
Diagnosis and treatment of SAD related disorders
|
US6313158B1
(en)
|
1997-06-20 |
2001-11-06 |
Sugen, Inc. |
Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
|
US6051593A
(en)
|
1997-06-20 |
2000-04-18 |
Sugen, Inc. |
3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
|
US6130238A
(en)
*
|
1997-06-20 |
2000-10-10 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
US6114371A
(en)
*
|
1997-06-20 |
2000-09-05 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
US6235769B1
(en)
|
1997-07-03 |
2001-05-22 |
Sugen, Inc. |
Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
|
ZA986729B
(en)
*
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitors of tyrosine kinases
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
US6251912B1
(en)
|
1997-08-01 |
2001-06-26 |
American Cyanamid Company |
Substituted quinazoline derivatives
|
US6329375B1
(en)
|
1997-08-05 |
2001-12-11 |
Sugen, Inc. |
Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
|
JP2001515032A
(ja)
*
|
1997-08-15 |
2001-09-18 |
セフアロン・インコーポレーテツド |
前立腺がんを治療するためのチロシンキナーゼ阻害剤と化学的去勢術の組み合わせ法
|
ES2289791T3
(es)
|
1997-08-22 |
2008-02-01 |
Astrazeneca Ab |
Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
|
EP1017384B1
(en)
*
|
1997-09-26 |
2004-11-10 |
Zentaris GmbH |
Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
|
US6133305A
(en)
|
1997-09-26 |
2000-10-17 |
Sugen, Inc. |
3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
|
UA71555C2
(en)
|
1997-10-06 |
2004-12-15 |
Zentaris Gmbh |
Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
|
US6323209B1
(en)
|
1997-11-06 |
2001-11-27 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
EP1049786A2
(en)
|
1998-01-21 |
2000-11-08 |
Sugen, Inc. |
Human orthologues of wart
|
US6531502B1
(en)
|
1998-01-21 |
2003-03-11 |
Sugen, Inc. |
3-Methylidenyl-2-indolinone modulators of protein kinase
|
CA2321307A1
(en)
|
1998-02-27 |
1999-09-02 |
Venkatachala L. Narayanan |
Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
US6514981B1
(en)
|
1998-04-02 |
2003-02-04 |
Sugen, Inc. |
Methods of modulating tyrosine protein kinase function with indolinone compounds
|
US6680170B2
(en)
|
1998-04-14 |
2004-01-20 |
Sugen, Inc. |
Polynucleotides encoding STE20-related protein kinases and methods of use
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
AU4317399A
(en)
|
1998-05-28 |
1999-12-13 |
Parker Hughes Institute |
Quinazolines for treating brain tumor
|
EP2020408B1
(en)
|
1998-05-29 |
2013-06-26 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitor
|
US6384223B1
(en)
|
1998-07-30 |
2002-05-07 |
American Home Products Corporation |
Substituted quinazoline derivatives
|
US6184226B1
(en)
*
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
JP2002523455A
(ja)
|
1998-08-31 |
2002-07-30 |
スージェン・インコーポレーテッド |
蛋白質キナーゼ活性の調節剤としての幾何学的に制限された2−インドリノン誘導体
|
US6680335B2
(en)
|
1998-09-28 |
2004-01-20 |
Sugen, Inc. |
Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
|
US6297258B1
(en)
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
BR9914164A
(pt)
|
1998-09-29 |
2001-06-26 |
American Cyanamid Co |
Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
CN1158266C
(zh)
|
1998-10-01 |
2004-07-21 |
阿斯特拉曾尼卡有限公司 |
化合物
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
CZ303692B6
(cs)
|
1999-02-10 |
2013-03-13 |
Astrazeneca Ab |
Chinazolinové deriváty jako inhibitory angiogeneze
|
DE19911509A1
(de)
*
|
1999-03-15 |
2000-09-21 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
ES2219319T3
(es)
|
1999-03-17 |
2004-12-01 |
Astrazeneca Ab |
Derivados de amida.
|
US7064114B2
(en)
*
|
1999-03-19 |
2006-06-20 |
Parker Hughes Institute |
Gel-microemulsion formulations
|
US6258820B1
(en)
|
1999-03-19 |
2001-07-10 |
Parker Hughes Institute |
Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
|
YU13200A
(sh)
|
1999-03-31 |
2002-10-18 |
Pfizer Products Inc. |
Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
|
CA2373815A1
(en)
*
|
1999-05-14 |
2000-11-23 |
Imclone Systems Incorporated |
Treatment of refractory human tumors with epidermal growth factor receptor antagonists
|
US6126917A
(en)
*
|
1999-06-01 |
2000-10-03 |
Hadasit Medical Research Services And Development Ltd. |
Epidermal growth factor receptor binding compounds for positron emission tomography
|
SK287010B6
(sk)
|
1999-06-21 |
2009-09-07 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Bicyklické heterocyklické zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
ES2295035T3
(es)
|
1999-07-09 |
2008-04-16 |
Glaxo Group Limited |
Anilinoquinazolinas como inhibidores de proteina tirosina quinasa.
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
ES2334879T3
(es)
*
|
1999-09-21 |
2010-03-17 |
Astrazeneca Ab |
Derivados de quinazolina y su uso como productos farmaceuticos.
|
EP1218356A1
(en)
*
|
1999-09-21 |
2002-07-03 |
AstraZeneca AB |
Quinazoline compounds and pharmaceutical compositions containing them
|
AU763033B2
(en)
*
|
1999-10-01 |
2003-07-10 |
Japan Energy Corporation |
Novel quinazoline derivatives
|
GB9924092D0
(en)
*
|
1999-10-13 |
1999-12-15 |
Zeneca Ltd |
Pyrimidine derivatives
|
EP1230225A2
(en)
*
|
1999-11-01 |
2002-08-14 |
Eli Lilly And Company |
Pharmaceutically active 4-substituted pyrimidine derivatives
|
GB9925958D0
(en)
|
1999-11-02 |
1999-12-29 |
Bundred Nigel J |
Therapeutic use
|
IL149034A0
(en)
*
|
1999-11-05 |
2002-11-10 |
Astrazeneca Ab |
Quinazoline derivatives as vegf inhibitors
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
UA75055C2
(uk)
*
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
KR20020084116A
(ko)
|
2000-02-07 |
2002-11-04 |
애보트 게엠베하 운트 콤파니 카게 |
2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도
|
GB0002952D0
(en)
*
|
2000-02-09 |
2000-03-29 |
Pharma Mar Sa |
Process for producing kahalalide F compounds
|
MXPA02008021A
(es)
|
2000-02-15 |
2004-04-05 |
Sugen Inc |
Indolinonas sustituidas con pirroles inhibidoras de proteinquinasas.
|
KR100858069B1
(ko)
*
|
2000-04-07 |
2008-09-22 |
아스트라제네카 아베 |
퀴나졸린 화합물류
|
UA73993C2
(uk)
*
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
CA2418083A1
(en)
*
|
2000-08-09 |
2002-02-14 |
Imclone Systems Incorporated |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
PL202812B1
(pl)
|
2000-08-21 |
2009-07-31 |
Astrazeneca Ab |
Pochodna chinazoliny, jej kompozycja famaceutyczna oraz jej zastosowanie
|
US6617329B2
(en)
|
2000-08-26 |
2003-09-09 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines and their use as medicaments
|
DE10042059A1
(de)
*
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
JP4564713B2
(ja)
|
2000-11-01 |
2010-10-20 |
ミレニアム・ファーマシューティカルズ・インコーポレイテッド |
窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法
|
US6582919B2
(en)
|
2001-06-11 |
2003-06-24 |
Response Genetics, Inc. |
Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
|
US7019012B2
(en)
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
AR042586A1
(es)
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
PT2762140T
(pt)
|
2001-02-19 |
2017-07-04 |
Novartis Ag |
Resumo
|
CA2439143A1
(en)
*
|
2001-02-26 |
2002-09-06 |
Mcgill University |
Combi-molecules having signal transduction inhibitory properties and dna damaging properties
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
MXPA03008560A
(es)
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
WO2002079498A1
(en)
*
|
2001-04-02 |
2002-10-10 |
Merck & Co., Inc. |
In vivo methods of determining activity of receptor-type kinase inhibitors
|
EP1381384B1
(en)
|
2001-04-24 |
2011-05-25 |
Merck Patent GmbH |
COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
PT1392359E
(pt)
*
|
2001-05-11 |
2010-01-27 |
Ludwig Inst For Cancer Res Ltd |
Proteínas de ligação específica e suas utilizações
|
WO2002092577A1
(en)
*
|
2001-05-14 |
2002-11-21 |
Astrazeneca Ab |
Quinazoline derivatives
|
MXPA03010401A
(es)
|
2001-05-16 |
2004-03-09 |
Novartis Ag |
Combinacion que comprende n-[5-[4- (4-metil- piperazino-metil) -benzoilamido] -2-metilfenil] -4-(3-piridil)-2 -pirimidin-amina, y un agente quimioterapeutico.
|
EP1408980A4
(en)
|
2001-06-21 |
2004-10-20 |
Ariad Pharma Inc |
NEW QUINAZOLINES AND THEIR USE
|
KR100397792B1
(ko)
|
2001-06-28 |
2003-09-13 |
한국과학기술연구원 |
4-(페닐아미노)-[1,4]디옥사노[2,3-g]퀴나졸린 유도체 및그의 제조방법
|
WO2003031438A1
(en)
|
2001-10-10 |
2003-04-17 |
Sugen, Inc. |
3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors
|
GB0126433D0
(en)
*
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
CN1627944A
(zh)
*
|
2002-01-17 |
2005-06-15 |
神经能质公司 |
取代的喹唑啉-4-基胺类似物作为辣椒辣素调节剂
|
US7268230B2
(en)
|
2002-02-01 |
2007-09-11 |
Astrazeneca Ab |
Quinazoline compounds
|
NZ534871A
(en)
*
|
2002-02-26 |
2007-05-31 |
Astrazeneca Ab |
Novel crystalline forms of the anti-cancer compound ZD1839
|
UA76325C2
(uk)
*
|
2002-02-26 |
2006-07-17 |
Астразенека Аб |
Лікарський препарат іресси, який містить водорозчинне похідне целюлози (варіанти), та спосіб його одержання
|
GB0204392D0
(en)
*
|
2002-02-26 |
2002-04-10 |
Astrazeneca Ab |
Pharmaceutical compound
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
TWI324597B
(en)
|
2002-03-28 |
2010-05-11 |
Astrazeneca Ab |
Quinazoline derivatives
|
US7078409B2
(en)
|
2002-03-28 |
2006-07-18 |
Beta Pharma, Inc. |
Fused quinazoline derivatives useful as tyrosine kinase inhibitors
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
KR20040103964A
(ko)
*
|
2002-04-16 |
2004-12-09 |
아스트라제네카 아베 |
암 치료를 위한 조합 요법
|
DE10221018A1
(de)
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
|
DE60324416D1
(de)
|
2002-05-16 |
2008-12-11 |
Novartis Ag |
Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie
|
EP2430923A1
(en)
|
2002-06-05 |
2012-03-21 |
Genentech, Inc. |
Compositions and methods for liver growth and liver protection
|
GB0221245D0
(en)
*
|
2002-09-13 |
2002-10-23 |
Astrazeneca Ab |
Chemical process
|
GB0223854D0
(en)
*
|
2002-10-12 |
2002-11-20 |
Astrazeneca Ab |
Therapeutic treatment
|
GB0304367D0
(en)
*
|
2003-02-26 |
2003-04-02 |
Pharma Mar Sau |
Methods for treating psoriasis
|
MXPA05006123A
(es)
*
|
2002-12-13 |
2005-09-30 |
Neurogen Corp |
Analogos de quinazolin-4-ilamina 2-sustituida como moduladores de receptores de capsaicina.
|
AU2003285614B2
(en)
|
2002-12-20 |
2009-05-14 |
Pfizer Products, Inc. |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
WO2004064718A2
(en)
*
|
2003-01-23 |
2004-08-05 |
T.K. Signal Ltd. |
Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof
|
US7223749B2
(en)
|
2003-02-20 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
EP1622941A2
(en)
*
|
2003-03-20 |
2006-02-08 |
ImClone Systems Incorporated |
Method of producing an antibody to epidermal growth factor receptor
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
US7417065B2
(en)
|
2003-05-19 |
2008-08-26 |
Irm Llc |
Immunosuppressant compounds and compositions
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
CA2527680A1
(en)
|
2003-05-30 |
2005-06-02 |
Astrazeneca Uk Limited |
Markers for responsiveness to an erbb receptor tyrosine kinase inhibitor
|
EP1638600A4
(en)
|
2003-06-09 |
2008-06-11 |
Samuel Waksal |
PROCESS FOR INHIBITING RECEPTOR TYROSINE KINASES WITH AN EXTRACELLULAR ANTAGONIST AND AN INTRA CELLULAR ANTAGONIST
|
DE602004009097T2
(de)
|
2003-06-10 |
2008-06-19 |
F. Hoffmann-La Roche Ag |
1.3.4-triaza-phenalen- und 1,3,4,6-tetraazaphenalen-derivate
|
MXPA06001079A
(es)
*
|
2003-07-29 |
2006-04-11 |
Astrazeneca Ab |
Derivados de piperidil quinazolina como inhibidores de cinasa de tirosina.
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
GB0317663D0
(en)
*
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Pharmaceutical composition
|
JP2007500689A
(ja)
*
|
2003-07-31 |
2007-01-18 |
サノフイ−アベンテイス |
アミノキノリン誘導体およびアデノシンa3リガンドとしてのそれらの使用
|
CA2534509A1
(en)
|
2003-08-06 |
2005-02-24 |
Sugen, Inc. |
Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein kinase inhibitors
|
GB0318422D0
(en)
|
2003-08-06 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
GB0321066D0
(en)
*
|
2003-09-09 |
2003-10-08 |
Pharma Mar Sau |
New antitumoral compounds
|
SI1667991T1
(sl)
|
2003-09-16 |
2008-10-31 |
Astrazeneca Ab |
Kinazolinski derivati kot inhibitorji tirozin kinaze
|
US20080234263A1
(en)
*
|
2003-09-16 |
2008-09-25 |
Laurent Francois Andre Hennequin |
Quinazoline Derivatives
|
US20070037837A1
(en)
*
|
2003-09-19 |
2007-02-15 |
Hennequin Laurent Francois A |
Quinazoline derivatives
|
US8318752B2
(en)
*
|
2003-09-19 |
2012-11-27 |
Astrazeneca Ab |
4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoyl-methyl)piperidin-4-yl]oxy}quinazoline, its pharmaceutically acceptable salts, and pharmaceutical compositions comprising the same
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
US20070043010A1
(en)
*
|
2003-09-25 |
2007-02-22 |
Astrazeneca Uk Limited |
Quinazoline derivatives
|
US7456189B2
(en)
|
2003-09-30 |
2008-11-25 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
|
US7232824B2
(en)
*
|
2003-09-30 |
2007-06-19 |
Scios, Inc. |
Quinazoline derivatives as medicaments
|
DE10349113A1
(de)
|
2003-10-17 |
2005-05-12 |
Boehringer Ingelheim Pharma |
Verfahren zur Herstellung von Aminocrotonylverbindungen
|
GB0324790D0
(en)
|
2003-10-24 |
2003-11-26 |
Astrazeneca Ab |
Amide derivatives
|
WO2005048928A2
(en)
*
|
2003-11-12 |
2005-06-02 |
George Mason Intellectual Property |
Methods for treating viral infection
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
CA2545711A1
(en)
*
|
2003-11-13 |
2005-06-02 |
Ambit Biosciences Corporation |
Urea derivatives as kinase modulators
|
US20100190150A1
(en)
*
|
2004-01-07 |
2010-07-29 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
|
BRPI0400869B8
(pt)
|
2004-03-02 |
2021-05-25 |
Univ Estadual Campinas Unicamp |
novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases
|
ES2315834T3
(es)
|
2004-02-03 |
2009-04-01 |
Astrazeneca Ab |
Derivados de quinazolina.
|
ES2554330T3
(es)
|
2004-02-19 |
2015-12-18 |
Rexahn Pharmaceuticals, Inc. |
Derivados de quinazolina y uso terapéutico de los mismos
|
DK1735348T3
(da)
|
2004-03-19 |
2012-07-16 |
Imclone Llc |
Humant anti-epidermalt vækstfaktorreceptorantistof
|
ES2741546T3
(es)
|
2004-03-31 |
2020-02-11 |
Massachusetts Gen Hospital |
Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
|
EP2253614B1
(en)
|
2004-04-07 |
2012-09-19 |
Novartis AG |
Inhibitors of IAP
|
CA2565721C
(en)
|
2004-05-06 |
2015-10-06 |
Bioresponse, L.L.C. |
Diindolymethane formulations for the treatment of leiomyomas
|
JP4205757B2
(ja)
|
2004-05-06 |
2009-01-07 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
4−フェニルアミノ−キナゾリン−6−イル−アミド
|
EP1773881A4
(en)
*
|
2004-05-13 |
2008-08-06 |
Imclone Systems Inc |
Inhibition of macrophage-stimulating protein receptor (RON)
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
JP2008504292A
(ja)
|
2004-06-24 |
2008-02-14 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
免疫増強用の化合物
|
NZ554017A
(en)
|
2004-10-12 |
2010-06-25 |
Astrazeneca Ab |
[(Quinazolin-4-yloxy)phenyl]acetamide derivatives
|
WO2006064196A1
(en)
|
2004-12-14 |
2006-06-22 |
Astrazeneca Ab |
Pyrazolopyrimidine compounds as antitumor agents
|
ATE497762T1
(de)
|
2004-12-30 |
2011-02-15 |
Bioresponse Llc |
Verwendung von diindolylmethan-verwandten indolen zur behandlung und prävention von erkrankungen im zusammenhang mit dem respiratory syncytial virus
|
US20060188498A1
(en)
*
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
US20090155247A1
(en)
*
|
2005-02-18 |
2009-06-18 |
Ashkenazi Avi J |
Methods of Using Death Receptor Agonists and EGFR Inhibitors
|
BRPI0606905B1
(pt)
|
2005-02-23 |
2021-06-01 |
Shionogi & Co., Ltd. |
Derivados de quinazolina tendo atividade inibitória de tirosina cinase e composição farmacêutica que os compreende
|
EP1856095B1
(en)
|
2005-02-26 |
2011-08-24 |
AstraZeneca AB |
Quinazoline derivatives as tyrosine kinase inhibitors
|
WO2006104971A1
(en)
*
|
2005-03-28 |
2006-10-05 |
Bristol-Myers Squibb Company |
Atp competitive kinase inhibitors
|
BRPI0607537A2
(pt)
*
|
2005-04-12 |
2009-09-15 |
Elan Pharma Int Ltd |
formulações de derivado de quinazolina nanoparticulado
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
CN101287761A
(zh)
|
2005-06-15 |
2008-10-15 |
先灵公司 |
抗-igf1r抗体制剂
|
CA2612449A1
(en)
|
2005-06-17 |
2006-12-28 |
Imclone Systems Incorporated |
Receptor antagonists for treatment of metastatic bone cancer
|
CA2620195A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
|
WO2007029251A2
(en)
|
2005-09-06 |
2007-03-15 |
T.K. Signal Ltd. |
Polyalkylene glycol derivatives of 4- (phenylamino)quinazolines useful as irreversible inhibitors of epidermal gr0wth fact0r receptor tyrosine kinase
|
JP2009508918A
(ja)
|
2005-09-20 |
2009-03-05 |
アストラゼネカ アクチボラグ |
癌治療のためのerbB受容体チロシンキナーゼ阻害剤としての4−(1H−インダゾール−5−イル]アミノ)キナゾリン化合物
|
AU2006201635A1
(en)
*
|
2005-10-20 |
2007-05-10 |
Ludwig Institute For Cancer Research |
Novel inhibitors and methods for their preparation
|
WO2007054550A1
(en)
|
2005-11-11 |
2007-05-18 |
Boehringer Ingelheim International Gmbh |
Quinazoline derivatives for the treatment of cancer diseases
|
CA2933875C
(en)
|
2005-11-21 |
2018-06-26 |
Novartis Ag |
40-o-(2-hydroxyethyl)-rapamycin for use as a sole drug substance in the treatment of carcinoid tumors arising from the foregut, midgut, or hindgut
|
JP2009520784A
(ja)
*
|
2005-12-22 |
2009-05-28 |
アストラゼネカ アクチボラグ |
キナゾリン誘導体、その製造方法および抗癌剤としてのその使用
|
CN101003514A
(zh)
|
2006-01-20 |
2007-07-25 |
上海艾力斯医药科技有限公司 |
喹唑啉衍生物、其制备方法及用途
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
CN101484587B
(zh)
|
2006-02-03 |
2014-02-12 |
英克隆有限责任公司 |
Igf-ir拮抗剂作为辅药用于前列腺癌的治疗
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
UY30183A1
(es)
|
2006-03-02 |
2007-10-31 |
Astrazeneca Ab |
Derivados de quinolina
|
JP2009528336A
(ja)
*
|
2006-03-02 |
2009-08-06 |
アストラゼネカ アクチボラグ |
キノリン誘導体
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
US20070231298A1
(en)
*
|
2006-03-31 |
2007-10-04 |
Cell Genesys, Inc. |
Cytokine-expressing cancer immunotherapy combinations
|
EP2591775A1
(en)
|
2006-04-05 |
2013-05-15 |
Novartis AG |
Combinations comprising mtor inhibitors for treating cancer
|
EP2314297A1
(en)
|
2006-04-05 |
2011-04-27 |
Novartis AG |
Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
|
AR060358A1
(es)
*
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
CN101472915A
(zh)
|
2006-04-19 |
2009-07-01 |
诺瓦提斯公司 |
吲唑化合物和抑制cdc7的方法
|
AU2007251282A1
(en)
|
2006-05-09 |
2007-11-22 |
Pfizer Products Inc. |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
AU2007247112B2
(en)
|
2006-05-09 |
2010-08-26 |
Novartis Ag |
Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
|
WO2008005469A2
(en)
|
2006-06-30 |
2008-01-10 |
Schering Corporation |
Igfbp2 biomarker
|
CN101100466B
(zh)
|
2006-07-05 |
2013-12-25 |
天津和美生物技术有限公司 |
不可逆蛋白质酪氨酸磷酰化酶抑制剂及其制备和应用
|
WO2008033749A2
(en)
*
|
2006-09-11 |
2008-03-20 |
Curis, Inc. |
Quinazoline based egfr inhibitors containing a zinc binding moiety
|
JP2010502743A
(ja)
*
|
2006-09-11 |
2010-01-28 |
キュリス,インコーポレイテッド |
抗増殖薬剤としての多機能性低分子
|
US7547781B2
(en)
|
2006-09-11 |
2009-06-16 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
AU2007296745B2
(en)
*
|
2006-09-11 |
2011-12-01 |
Curis, Inc. |
Quinazoline based EGFR inhibitors
|
CA2662236A1
(en)
|
2006-09-12 |
2008-03-20 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of cancer
|
BRPI0717586A2
(pt)
|
2006-09-18 |
2013-10-29 |
Boehringer Ingelheim Int |
Método para tratar câncer apresentando mutações do egfr
|
EP2077819A4
(en)
*
|
2006-09-28 |
2011-05-25 |
Follica Inc |
METHODS, MATERIALS, AND COMPOSITIONS FOR GENERATING NEW CELLULAR FOLLICLES AND PUSHING HAIR
|
ATE502943T1
(de)
|
2006-09-29 |
2011-04-15 |
Novartis Ag |
Pyrazolopyrimidine als pi3k-lipidkinasehemmer
|
JO3598B1
(ar)
*
|
2006-10-10 |
2020-07-05 |
Infinity Discovery Inc |
الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
|
US8586621B2
(en)
|
2006-10-27 |
2013-11-19 |
Michael A. Zeligs |
Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
EP2126127B1
(en)
|
2007-01-25 |
2016-09-28 |
Dana-Farber Cancer Institute, Inc. |
Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
|
EP2118075A1
(de)
|
2007-02-06 |
2009-11-18 |
Boehringer Ingelheim International GmbH |
Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
CN101245050A
(zh)
|
2007-02-14 |
2008-08-20 |
上海艾力斯医药科技有限公司 |
4-苯胺喹唑啉衍生物的盐
|
MX2009008584A
(es)
|
2007-02-15 |
2009-08-18 |
Novartis Ag |
Combinacion de lbh589 con otros agentes terapeuticos para el tratamiento de cancer.
|
AU2008227123B2
(en)
|
2007-03-15 |
2014-03-27 |
Ludwig Institute For Cancer Research Ltd. |
Treatment method using EGFR antibodies and src inhibitors and related formulations
|
ES2465673T3
(es)
|
2007-04-16 |
2014-06-06 |
Hutchison Medipharma Enterprises Limited |
Derivados de pirimidina
|
EA016679B1
(ru)
|
2007-04-18 |
2012-06-29 |
Пфайзер Продактс Инк. |
Сульфониламидные производные для лечения аномального роста клеток
|
WO2008141843A1
(en)
*
|
2007-05-24 |
2008-11-27 |
Bayer Schering Pharma Aktiengesellschaft |
Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors
|
CN101896503B
(zh)
*
|
2007-08-14 |
2018-05-22 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
CA2698944C
(en)
|
2007-09-10 |
2015-06-16 |
Curis, Inc. |
Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety
|
US8119616B2
(en)
*
|
2007-09-10 |
2012-02-21 |
Curis, Inc. |
Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
|
CN101861159A
(zh)
*
|
2007-10-19 |
2010-10-13 |
马尔药品公司 |
改进的抗肿瘤治疗
|
EP2212432A4
(en)
*
|
2007-10-22 |
2011-10-19 |
Schering Corp |
COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES
|
MY150054A
(en)
*
|
2007-10-29 |
2013-11-29 |
Natco Pharma Ltd |
Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
|
CN101909630A
(zh)
|
2007-11-02 |
2010-12-08 |
新加坡科技研究局 |
预防和治疗肿瘤的方法和化合物
|
EP2060565A1
(en)
|
2007-11-16 |
2009-05-20 |
4Sc Ag |
Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
|
US20110053991A1
(en)
*
|
2007-11-19 |
2011-03-03 |
Gore Lia |
Treatment of Histone Deacetylase Mediated Disorders
|
WO2009067242A2
(en)
*
|
2007-11-20 |
2009-05-28 |
Imclone Llc |
Co-crystal of antibody 11f8 fab fragment and egfr extracellular domain and uses thereof
|
UY31478A1
(es)
*
|
2007-11-21 |
2009-07-17 |
|
Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
|
EP2072502A1
(de)
*
|
2007-12-20 |
2009-06-24 |
Bayer Schering Pharma Aktiengesellschaft |
Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
|
PE20091523A1
(es)
|
2007-12-20 |
2009-10-29 |
Novartis Ag |
Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k)
|
ES2593321T3
(es)
|
2008-01-18 |
2016-12-07 |
Natco Pharma Limited |
Derivados de 6,7-dialcoxi-quinazolina útiles para el tratamiento de trastornos relacionados con el cáncer
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
JP2011515330A
(ja)
*
|
2008-01-30 |
2011-05-19 |
ファルマ・マール・ソシエダード・アノニマ |
改良抗腫瘍治療剤
|
EA019709B1
(ru)
|
2008-02-07 |
2014-05-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Спирогетероциклы и их применение в качестве лекарственных средств
|
DE102008009609A1
(de)
|
2008-02-18 |
2009-08-20 |
Freie Universität Berlin |
Substituierte 4-(Indol-3-yl)chinazoline und deren Verwendung und Herstellung
|
BRPI0908049A2
(pt)
*
|
2008-03-05 |
2015-08-11 |
Novartis Ag |
Uso de derivados de pririmidina para o tratamento de doenças dependentes de egfr ou de doenças que possuem resistência adquirida a agentes que são direcionados aos membros da família de egfr
|
CN101965192A
(zh)
*
|
2008-03-07 |
2011-02-02 |
法马马有限公司 |
改善的抗肿瘤治疗
|
US8222424B2
(en)
|
2008-03-24 |
2012-07-17 |
Novartis Ag |
Arylsulfonamide-based matrix metalloprotease inhibitors
|
EP2628726A1
(en)
|
2008-03-26 |
2013-08-21 |
Novartis AG |
Hydroxamate-based inhibitors of deacetylases b
|
CN102046179B
(zh)
*
|
2008-04-09 |
2015-01-14 |
英菲尼提制药公司 |
脂肪酸酰胺水解酶抑制剂
|
US7829574B2
(en)
|
2008-05-09 |
2010-11-09 |
Hutchison Medipharma Enterprises Limited |
Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
|
EA019183B1
(ru)
|
2008-05-13 |
2014-01-30 |
Астразенека Аб |
Фумаратная соль 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина
|
CN101584696A
(zh)
|
2008-05-21 |
2009-11-25 |
上海艾力斯医药科技有限公司 |
包含喹唑啉衍生物的组合物及制备方法、用途
|
US8426430B2
(en)
*
|
2008-06-30 |
2013-04-23 |
Hutchison Medipharma Enterprises Limited |
Quinazoline derivatives
|
WO2010015522A1
(de)
|
2008-08-08 |
2010-02-11 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
US7737157B2
(en)
*
|
2008-08-29 |
2010-06-15 |
Hutchison Medipharma Enterprises Limited |
Pyrimidine compounds
|
WO2010043050A1
(en)
|
2008-10-16 |
2010-04-22 |
Celator Pharmaceuticals Corporation |
Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
|
EP2349235A1
(en)
|
2008-11-07 |
2011-08-03 |
Triact Therapeutics, Inc. |
Use of catecholic butane derivatives in cancer therapy
|
US20100222371A1
(en)
*
|
2008-11-20 |
2010-09-02 |
Children's Medical Center Corporation |
Prevention of surgical adhesions
|
KR20110112352A
(ko)
|
2008-12-18 |
2011-10-12 |
노파르티스 아게 |
1-(4-{l-[(e)-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노]-에틸}-2-에틸-벤질)-아제티딘-3-카르복실산의 신규한 다형체 형태
|
US20120115840A1
(en)
|
2008-12-18 |
2012-05-10 |
Lech Ciszewski |
Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid
|
EP2379499B1
(en)
|
2008-12-18 |
2014-04-09 |
Novartis AG |
Hydrochloride salt of 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl)-2-ethyl-benzyl)-azetidine-3-carboxylic acid
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
JP2012516345A
(ja)
|
2009-01-29 |
2012-07-19 |
ノバルティス アーゲー |
星細胞腫治療用置換ベンゾイミダゾール
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
EP2400990A2
(en)
|
2009-02-26 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
In situ methods for monitoring the emt status of tumor cells in vivo
|
EP2401614A1
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099364A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
JP2012520893A
(ja)
|
2009-03-18 |
2012-09-10 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
Egfr阻害薬及びigf−1r阻害剤の投与を含む組み合わせ癌治療
|
CN102356092B
(zh)
|
2009-03-20 |
2014-11-05 |
霍夫曼-拉罗奇有限公司 |
双特异性抗-her抗体
|
US8541581B2
(en)
|
2009-04-07 |
2013-09-24 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of fatty acid amide hydrolase
|
CA2757679A1
(en)
|
2009-04-07 |
2010-10-14 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of fatty acid amide hydrolase
|
UA105794C2
(uk)
|
2009-06-26 |
2014-06-25 |
Новартіс Аг |
1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
WO2011003853A2
(en)
|
2009-07-06 |
2011-01-13 |
Boehringer Ingelheim International Gmbh |
Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
|
US9050341B2
(en)
|
2009-07-14 |
2015-06-09 |
Natco Pharma Limited |
Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
AU2010283806A1
(en)
|
2009-08-12 |
2012-03-01 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
ES2709108T3
(es)
|
2009-08-17 |
2019-04-15 |
Intellikine Llc |
Compuestos heterocíclicos y usos de los mismos
|
AU2010284972A1
(en)
|
2009-08-20 |
2012-03-08 |
Novartis Ag |
Heterocyclic oxime compounds
|
EA201200321A1
(ru)
|
2009-08-26 |
2012-09-28 |
Новартис Аг |
Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4
|
WO2011027249A2
(en)
|
2009-09-01 |
2011-03-10 |
Pfizer Inc. |
Benzimidazole derivatives
|
LT2473487T
(lt)
|
2009-09-03 |
2017-01-10 |
Bristol-Myers Squibb Company |
Chinazolinai kaip kalio jonų kanalų inhibitoriai
|
IN2012DN02139A
(uk)
|
2009-09-10 |
2015-08-07 |
Novartis Ag |
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
AU2010310786B2
(en)
|
2009-10-23 |
2014-03-27 |
Eli Lilly And Company |
AKT inhibitors
|
WO2011053779A2
(en)
|
2009-10-30 |
2011-05-05 |
Bristol-Myers Squibb Company |
Methods for treating cancer in patients having igf-1r inhibitor resistance
|
MX2012005293A
(es)
|
2009-11-04 |
2012-06-19 |
Novartis Ag |
Derivados de sulfonamida heterociclicos utiles como inhibidores de mek.
|
WO2011060246A2
(en)
|
2009-11-12 |
2011-05-19 |
Genentech, Inc. |
A method of promoting dendritic spine density
|
US20120316187A1
(en)
|
2009-11-13 |
2012-12-13 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
US20110130711A1
(en)
*
|
2009-11-19 |
2011-06-02 |
Follica, Inc. |
Hair growth treatment
|
US20110237540A1
(en)
|
2009-11-23 |
2011-09-29 |
Crawford Thomas C |
Cyclodextrin-based polymers for therapeutic delivery
|
WO2011064211A1
(en)
|
2009-11-25 |
2011-06-03 |
Novartis Ag |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
JP5456908B2
(ja)
|
2009-12-08 |
2014-04-02 |
ノバルティス アーゲー |
ヘテロ環式スルホンアミド誘導体
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
CN102712640A
(zh)
|
2010-01-12 |
2012-10-03 |
弗·哈夫曼-拉罗切有限公司 |
三环杂环化合物、其组合物和应用方法
|
US20110178287A1
(en)
|
2010-01-19 |
2011-07-21 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
EP2531511A1
(en)
*
|
2010-02-03 |
2012-12-12 |
Infinity Pharmaceuticals, Inc. |
Fatty acid amide hydrolase inhibitors
|
RU2587619C2
(ru)
|
2010-02-18 |
2016-06-20 |
Дженентек, Инк. |
Антагонисты неурегулина и применение их в лечении злокачественного новообразования
|
AU2011229542A1
(en)
*
|
2010-03-16 |
2012-11-08 |
Merck Patent Gmbh |
Morpholinylquinazolines
|
KR20130001272A
(ko)
|
2010-03-17 |
2013-01-03 |
에프. 호프만-라 로슈 아게 |
이미다조피리딘 및 푸린 화합물, 조성물 및 사용 방법
|
WO2011119995A2
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc. |
Formulations and methods of use
|
TWI406853B
(zh)
*
|
2010-04-07 |
2013-09-01 |
Dev Center Biotechnology |
Egfr與vegfr-2雙重抑制劑及其用途與製法
|
EP2558864A1
(en)
|
2010-04-16 |
2013-02-20 |
Genentech, Inc. |
Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
|
CN102947274A
(zh)
|
2010-06-17 |
2013-02-27 |
诺瓦提斯公司 |
联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
|
WO2011157793A1
(en)
|
2010-06-17 |
2011-12-22 |
Novartis Ag |
Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
DK2612151T3
(en)
|
2010-08-31 |
2017-10-02 |
Genentech Inc |
BIOMARKETS AND METHODS OF TREATMENT
|
KR20130051507A
(ko)
|
2010-09-15 |
2013-05-20 |
에프. 호프만-라 로슈 아게 |
아자벤조티아졸 화합물, 조성물 및 사용 방법
|
JP2013537210A
(ja)
|
2010-09-16 |
2013-09-30 |
ノバルティス アーゲー |
17α−ヒドロキシラーゼ/C17,20−リアーゼ阻害剤
|
EP2630134B9
(en)
|
2010-10-20 |
2018-04-18 |
Pfizer Inc |
Pyridine-2- derivatives as smoothened receptor modulators
|
KR20140009259A
(ko)
|
2010-11-19 |
2014-01-22 |
에프. 호프만-라 로슈 아게 |
피라졸로피리딘 및 tyk2 억제제로서 이의 용도
|
BR112013015449A2
(pt)
|
2010-12-21 |
2016-09-20 |
Novartis Ag |
compostos de bi-heteroarila como inibidores de vps23
|
EP2468883A1
(en)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
UY33883A
(es)
|
2011-01-31 |
2012-08-31 |
Novartis Ag |
Novedosos derivados heterocíclicos
|
EP2673277A1
(en)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
EP2492688A1
(en)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
US9127000B2
(en)
|
2011-02-23 |
2015-09-08 |
Intellikine, LLC. |
Heterocyclic compounds and uses thereof
|
KR20210043016A
(ko)
|
2011-03-04 |
2021-04-20 |
뉴젠 세러퓨틱스 인코포레이티드 |
알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
|
ES2609578T3
(es)
|
2011-03-04 |
2017-04-21 |
Glaxosmithkline Intellectual Property Development Limited |
Amino-quinolinas como inhibidores de quinasa
|
CN103492390A
(zh)
|
2011-03-08 |
2014-01-01 |
诺瓦提斯公司 |
氟苯基双环杂芳基化合物
|
US9321759B2
(en)
|
2011-03-17 |
2016-04-26 |
The Trustees Of The University Of Pennsylvania |
Methods and use of bifunctional enzyme-building clamp-shaped molecules
|
US9295676B2
(en)
|
2011-03-17 |
2016-03-29 |
The Trustees Of The University Of Pennsylvania |
Mutation mimicking compounds that bind to the kinase domain of EGFR
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
GB201106870D0
(en)
|
2011-04-26 |
2011-06-01 |
Univ Belfast |
Marker
|
JP6002210B2
(ja)
|
2011-04-28 |
2016-10-05 |
ノバルティス アーゲー |
17α−ヒドロキシラーゼ/C17,20−リアーゼ阻害剤
|
CN102918029B
(zh)
|
2011-05-17 |
2015-06-17 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
CA2838029A1
(en)
|
2011-06-09 |
2012-12-13 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
WO2012175487A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
US8859535B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
KR20140025530A
(ko)
|
2011-06-27 |
2014-03-04 |
노파르티스 아게 |
테트라히드로-피리도-피리미딘 유도체의 고체 형태 및 염
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
WO2013024011A1
(en)
|
2011-08-12 |
2013-02-21 |
F. Hoffmann-La Roche Ag |
Indazole compounds, compositions and methods of use
|
EP2744824A1
(en)
|
2011-08-17 |
2014-06-25 |
F.Hoffmann-La Roche Ag |
Neuregulin antibodies and uses thereof
|
TWI547494B
(zh)
|
2011-08-18 |
2016-09-01 |
葛蘭素史克智慧財產發展有限公司 |
作為激酶抑制劑之胺基喹唑啉類
|
KR20140057356A
(ko)
|
2011-08-31 |
2014-05-12 |
제넨테크, 인크. |
진단 마커
|
BR112014006223A8
(pt)
|
2011-09-15 |
2018-01-09 |
Novartis Ag |
3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação
|
CA2845409A1
(en)
|
2011-09-20 |
2013-03-28 |
Yingjie Lai |
Imidazopyridine compounds, compositions and methods of use
|
AU2012311184A1
(en)
|
2011-09-22 |
2014-03-06 |
Pfizer Inc. |
Pyrrolopyrimidine and purine derivatives
|
US20130084287A1
(en)
|
2011-09-30 |
2013-04-04 |
Genentech, Inc. |
Diagnostic markers
|
WO2013056069A1
(en)
|
2011-10-13 |
2013-04-18 |
Bristol-Myers Squibb Company |
Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
|
WO2013061305A1
(en)
|
2011-10-28 |
2013-05-02 |
Novartis Ag |
Novel purine derivatives and their use in the treatment of disease
|
EP2785717B1
(en)
|
2011-11-29 |
2016-01-13 |
Novartis AG |
Pyrazolopyrrolidine compounds
|
SG11201402510TA
(en)
|
2011-11-30 |
2014-06-27 |
Genentech Inc |
Erbb3 mutations in cancer
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
WO2013091507A1
(zh)
|
2011-12-20 |
2013-06-27 |
Qian Wei |
杂环胺基烷氧基取代的喹唑啉衍生物及其用途
|
PE20141598A1
(es)
|
2011-12-22 |
2014-11-14 |
Novartis Ag |
Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
|
WO2013093850A1
(en)
|
2011-12-22 |
2013-06-27 |
Novartis Ag |
Quinoline derivatives
|
MX2014007730A
(es)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
|
KR20140107578A
(ko)
|
2011-12-23 |
2014-09-04 |
노파르티스 아게 |
Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
|
WO2013096060A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
CN104136429A
(zh)
|
2011-12-23 |
2014-11-05 |
诺华股份有限公司 |
用于抑制bcl2与结合配偶体相互作用的化合物
|
MX2014007729A
(es)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
EP2752413B1
(en)
|
2012-03-26 |
2016-03-23 |
Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences |
Quinazoline derivative and application thereof
|
EP2831115A1
(en)
|
2012-03-27 |
2015-02-04 |
F. Hoffmann-La Roche AG |
Diagnosis and treatments relating to her3 inhibitors
|
CN104245701A
(zh)
|
2012-04-03 |
2014-12-24 |
诺华有限公司 |
有酪氨酸激酶抑制剂的组合产品和其应用
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
CN103373966A
(zh)
*
|
2012-04-17 |
2013-10-30 |
南京大学 |
一类4-苯胺喹唑啉类酰胺衍生物及其制备方法与用途
|
US10213432B2
(en)
|
2012-05-16 |
2019-02-26 |
Novartis Ag |
Dosage regimen for a PI-3 kinase inhibitor
|
EP2855483B1
(en)
|
2012-05-24 |
2017-10-25 |
Novartis AG |
Pyrrolopyrrolidinone compounds
|
JP6427097B2
(ja)
|
2012-06-15 |
2018-11-21 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
癌を処置するための組成物および該組成物を製造するための方法
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
US9738643B2
(en)
|
2012-08-06 |
2017-08-22 |
Duke University |
Substituted indazoles for targeting Hsp90
|
US9637523B2
(en)
|
2012-08-31 |
2017-05-02 |
Westfaelische Wilhelms-Universitaet Muenster |
Methods and peptides for preventing and treating a BCR-ABL and a C-ABL associated disease
|
AR092529A1
(es)
|
2012-09-13 |
2015-04-22 |
Glaxosmithkline Llc |
Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
|
TW201425307A
(zh)
|
2012-09-13 |
2014-07-01 |
Glaxosmithkline Llc |
作為激酶抑制劑之胺基-喹啉類
|
CN110787285A
(zh)
|
2012-11-05 |
2020-02-14 |
达纳-法伯癌症研究所股份有限公司 |
Xbp1、cd138和cs1肽、包括所述肽的药物组合物及使用所述肽和组合物的方法
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
WO2014115077A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Substituted purinone compounds
|
EP2948453B1
(en)
|
2013-01-22 |
2017-08-02 |
Novartis AG |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
RU2721418C2
(ru)
|
2013-02-01 |
2020-05-19 |
Веллстат Терапьютикс Корпорейшн |
Соединения амина, имеющие противовоспалительную, противогрибковую, противопаразитарную и противораковую активность
|
WO2014130657A1
(en)
|
2013-02-20 |
2014-08-28 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
BR112015019624A2
(pt)
|
2013-02-21 |
2017-07-18 |
Glaxosmithkline Ip Dev Ltd |
quinazolinas como inibidores de quinase
|
KR20150118159A
(ko)
|
2013-02-22 |
2015-10-21 |
에프. 호프만-라 로슈 아게 |
암의 치료 방법 및 약물 내성의 예방 방법
|
EP2961412A4
(en)
|
2013-02-26 |
2016-11-09 |
Triact Therapeutics Inc |
CANCER THERAPY
|
US9468681B2
(en)
|
2013-03-01 |
2016-10-18 |
California Institute Of Technology |
Targeted nanoparticles
|
UA115686C2
(uk)
|
2013-03-06 |
2017-12-11 |
Астразенека Аб |
Хіназолінові інгібітори активувальних мутантних форм рецептора епідермального фактора росту
|
RU2015137610A
(ru)
|
2013-03-06 |
2017-04-10 |
Дженентек, Инк. |
Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
|
KR20150130491A
(ko)
|
2013-03-13 |
2015-11-23 |
제넨테크, 인크. |
피라졸로 화합물 및 그것의 용도
|
KR20150127203A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
Mek 억제제 화합물과 her3/egfr 억제제 화합물의 조합물 및 사용 방법
|
CA2905070A1
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
US20160143910A1
(en)
|
2013-03-15 |
2016-05-26 |
Constellation Pharmaceuticals, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
EP2968340A4
(en)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
COMBINING KINASE INHIBITORS AND USES THEREOF
|
EP2976085A1
(en)
|
2013-03-21 |
2016-01-27 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
WO2014147631A1
(en)
|
2013-03-22 |
2014-09-25 |
Natco Pharma Limited |
Formulation comprising gefitinib as oral suspension
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
ES2638317T3
(es)
|
2013-04-04 |
2017-10-19 |
Janssen Pharmaceutica Nv |
Nuevos derivados de N-(2,3-dihidro-1H-pirrolo[2,3-b]piridin-5-il)-4-quinazolinamina y N-(2,3-dihidro-1H-indol-5-il)-4-quinazolinamina como inhibidores de PERK
|
CN103275019B
(zh)
*
|
2013-04-26 |
2016-05-18 |
浙江工业大学 |
4-[3-氯-4-取代苯胺基]-6-取代甲氧基甲酰氨基喹唑啉类化合物及制备和应用
|
CN103382182B
(zh)
*
|
2013-05-17 |
2016-08-10 |
河北医科大学 |
苯基脲偶联喹唑啉类化合物及其制备方法、药物组合物及药物用途
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
CN103304491A
(zh)
*
|
2013-06-17 |
2013-09-18 |
连云港盛和生物科技有限公司 |
一种吉非替尼的制备方法
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
MX2016002794A
(es)
|
2013-09-05 |
2016-09-13 |
Genentech Inc |
Compuestos antiproliferativos.
|
EP3044593A4
(en)
|
2013-09-09 |
2017-05-17 |
Triact Therapeutics, Inc. |
Cancer therapy
|
CA2920059A1
(en)
|
2013-09-22 |
2015-03-26 |
Calitor Sciences, Llc |
Substituted aminopyrimidine compounds and methods of use
|
CN103483276B
(zh)
*
|
2013-09-22 |
2018-04-17 |
南京恒道医药科技有限公司 |
一种凡德他尼杂质的制备方法
|
TW201605857A
(zh)
|
2013-10-03 |
2016-02-16 |
赫孚孟拉羅股份公司 |
Cdk8之醫療性抑制劑及其用途
|
CA2925598A1
(en)
|
2013-10-18 |
2015-04-23 |
Genentech, Inc. |
Anti-rspo antibodies and methods of use
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
JP2016539149A
(ja)
|
2013-12-06 |
2016-12-15 |
ノバルティス アーゲー |
アルファ−アイソフォーム選択的ホスファチジルイノシトール3−キナーゼ阻害剤の投薬レジメン
|
MX2016007887A
(es)
|
2013-12-17 |
2016-10-28 |
Genentech Inc |
Metodos de tratamiento de canceres positivos a her2 usando antagonistas de union del eje de pd-1 y anticuerpos anti-her2.
|
SG11201604979WA
(en)
|
2013-12-17 |
2016-07-28 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
MA39776A
(fr)
|
2014-03-24 |
2017-02-01 |
Hoffmann La Roche |
Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
|
WO2015148714A1
(en)
|
2014-03-25 |
2015-10-01 |
Duke University |
Heat shock protein 70 (hsp-70) receptor ligands
|
RU2715236C2
(ru)
|
2014-03-26 |
2020-02-26 |
Астекс Терапьютикс Лтд |
Комбинации
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
EP3327006B1
(en)
|
2014-03-28 |
2020-05-20 |
Calitor Sciences, LLC |
Substituted heteroaryl compounds and methods of use
|
PT3126394T
(pt)
|
2014-03-31 |
2019-12-19 |
Hoffmann La Roche |
Anticorpos anti-ox40 e métodos de utilização
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
JP2017513931A
(ja)
|
2014-04-03 |
2017-06-01 |
インビクタス オンコロジー ピーヴィティー.リミテッド |
超分子コンビナトリアル治療薬
|
WO2015156674A2
(en)
|
2014-04-10 |
2015-10-15 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
NZ725496A
(en)
|
2014-04-30 |
2019-11-29 |
Pfizer |
Cycloalkyl-linked diheterocycle derivatives
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
MX2017001461A
(es)
|
2014-07-31 |
2017-05-11 |
Novartis Ag |
Terapia de combinacion.
|
WO2016036873A1
(en)
|
2014-09-05 |
2016-03-10 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
EP3193866A1
(en)
|
2014-09-19 |
2017-07-26 |
Genentech, Inc. |
Use of cbp/ep300 and bet inhibitors for treatment of cancer
|
JP6783230B2
(ja)
|
2014-10-10 |
2020-11-11 |
ジェネンテック, インコーポレイテッド |
ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物
|
RU2017119231A
(ru)
|
2014-11-03 |
2018-12-06 |
Дженентек, Инк. |
Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40
|
CA2966523A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Assays for detecting t cell immune subsets and methods of use thereof
|
SG11201703376QA
(en)
|
2014-11-06 |
2017-05-30 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
EP3218376B1
(en)
|
2014-11-10 |
2019-12-25 |
Genentech, Inc. |
Bromodomain inhibitors and uses thereof
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
US20160166685A1
(en)
|
2014-11-17 |
2016-06-16 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
EP3224258B1
(en)
|
2014-11-27 |
2019-08-14 |
Genentech, Inc. |
4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
|
SG11201704707PA
(en)
|
2014-12-23 |
2017-07-28 |
Genentech Inc |
Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
|
EP3699290A1
(en)
|
2014-12-24 |
2020-08-26 |
F. Hoffmann-La Roche AG |
Therapeutic, diagnostic, and prognostic methods for cancer
|
EP3240908A2
(en)
|
2014-12-30 |
2017-11-08 |
F. Hoffmann-La Roche AG |
Methods and compositions for prognosis and treatment of cancers
|
WO2016112298A1
(en)
|
2015-01-09 |
2016-07-14 |
Genentech, Inc. |
Pyridazinone derivatives and their use in the treatment of cancer
|
CN107406418B
(zh)
|
2015-01-09 |
2021-10-29 |
基因泰克公司 |
4,5-二氢咪唑衍生物及其作为组蛋白脱甲基酶(kdm2b)抑制剂的用途
|
EP3242872B1
(en)
|
2015-01-09 |
2019-07-03 |
Genentech, Inc. |
(piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
|
JP6709792B2
(ja)
|
2015-01-29 |
2020-06-17 |
ジェネンテック, インコーポレイテッド |
治療用化合物およびその使用
|
WO2016123387A1
(en)
|
2015-01-30 |
2016-08-04 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
JOP20200201A1
(ar)
|
2015-02-10 |
2017-06-16 |
Astex Therapeutics Ltd |
تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
EP3280736A1
(en)
|
2015-04-07 |
2018-02-14 |
F. Hoffmann-La Roche AG |
Antigen binding complex having agonistic activity and methods of use
|
MX2017014381A
(es)
|
2015-05-12 |
2018-03-02 |
Genentech Inc |
Metodos terapeuticos y diagnosticos para cancer.
|
CN107532217A
(zh)
|
2015-05-29 |
2018-01-02 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
CN107810011A
(zh)
|
2015-06-08 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗ox40抗体治疗癌症的方法
|
CN107750164A
(zh)
|
2015-06-08 |
2018-03-02 |
豪夫迈·罗氏有限公司 |
使用抗ox40抗体和pd‑1轴结合拮抗剂治疗癌症的方法
|
CN107771076A
(zh)
|
2015-06-17 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
|
CN107922609B
(zh)
|
2015-07-01 |
2020-04-24 |
加州理工学院 |
基于阳离子粘酸聚合物的递送系统
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
CN105001167B
(zh)
*
|
2015-07-16 |
2018-01-05 |
西安交通大学 |
1‑取代苯基‑3‑(4‑取代苯基氨基‑6‑喹唑啉基)脲类化合物及制备方法和用途
|
PL3341376T3
(pl)
|
2015-08-26 |
2021-08-02 |
Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Skondensowane związki tricykliczne jako inhibitory kinaz białkowych
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
BR112018005862A2
(pt)
|
2015-09-25 |
2018-10-16 |
Genentech, Inc. |
anticorpos, anticorpos isolados, polinucleotídeo, vetor, célula hospedeira, método de produção do anticorpo, imunoconjugado, composição, usos dos anticorpos, métodos para tratar ou retardar a progressão de um câncer e de uma doença e para aumentar, potencializar ou estimular uma resposta ou função imune e kit
|
JP6740354B2
(ja)
|
2015-10-05 |
2020-08-12 |
ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク |
オートファジーの流れ及びホスホリパーゼd及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
|
US11078528B2
(en)
|
2015-10-12 |
2021-08-03 |
Advanced Cell Diagnostics, Inc. |
In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto
|
AU2016347881A1
(en)
|
2015-11-02 |
2018-05-10 |
Novartis Ag |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
EP3978500B1
(en)
|
2015-12-16 |
2023-11-22 |
Genentech, Inc. |
Process for the preparation of tricyclic pi3k inhibitor compounds
|
US10259805B2
(en)
|
2015-12-30 |
2019-04-16 |
Synthon B.V. |
Process for making crystalline form a of gefitinib
|
WO2017118675A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
EP3402536A4
(en)
|
2016-01-13 |
2019-07-03 |
Hadasit Medical Research Services And Development Limited |
RADIOACTIVELY MARKED ERLOTINIB ANALOGUES AND USES THEREOF
|
KR102500659B1
(ko)
|
2016-02-29 |
2023-02-16 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
US20170319688A1
(en)
|
2016-04-14 |
2017-11-09 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
CN109154027A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
JP7503887B2
(ja)
|
2016-04-15 |
2024-06-21 |
ジェネンテック, インコーポレイテッド |
がんを監視及び治療するための方法
|
CN109072311A
(zh)
|
2016-04-15 |
2018-12-21 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
WO2017184956A1
(en)
|
2016-04-22 |
2017-10-26 |
Duke University |
Compounds and methods for targeting hsp90
|
CN109476663B
(zh)
|
2016-05-24 |
2021-11-09 |
基因泰克公司 |
用于治疗癌症的吡唑并吡啶衍生物
|
WO2017205536A2
(en)
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
WO2017214373A1
(en)
|
2016-06-08 |
2017-12-14 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
EP3497129A1
(en)
|
2016-08-08 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
WO2018039205A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating breast cancer
|
WO2018039203A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating multiple myeloma
|
RU2019112860A
(ru)
|
2016-09-27 |
2020-10-30 |
Серо Терапьютикс, Инк. |
Молекулы химерных интернализационных рецепторов
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
US10927083B2
(en)
|
2016-09-29 |
2021-02-23 |
Duke University |
Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
|
CN110418851A
(zh)
|
2016-10-06 |
2019-11-05 |
基因泰克公司 |
癌症的治疗和诊断方法
|
WO2018078143A1
(en)
|
2016-10-28 |
2018-05-03 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
|
CN110267678A
(zh)
|
2016-10-29 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
抗mic抗体和使用方法
|
UA124474C2
(uk)
|
2016-12-22 |
2021-09-22 |
Емджен Інк. |
БЕНЗІЗОТІАЗОЛЬНІ, ІЗОТІАЗОЛО[3,4-b]ПІРИДИНОВІ, ХІНАЗОЛІНОВІ, ФТАЛАЗИНОВІ, ПІРИДО[2,3-d]ПІРИДАЗИНОВІ Й ПІРИДО[2,3-d]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ G12C KRAS ДЛЯ ЛІКУВАННЯ РАКУ ЛЕГЕНІ, РАКУ ПІДШЛУНКОВОЇ ЗАЛОЗИ АБО КОЛОРЕКТАЛЬНОГО РАКУ
|
EP3567030B1
(en)
*
|
2016-12-30 |
2022-02-09 |
Medshine Discovery Inc. |
Quinazoline compound for egfr inhibition
|
CN110546277B
(zh)
|
2017-03-01 |
2024-06-11 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
AU2018250875A1
(en)
|
2017-04-13 |
2019-10-03 |
F. Hoffmann-La Roche Ag |
An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
TWI799426B
(zh)
|
2017-06-22 |
2023-04-21 |
英商克拉德夫製藥有限公司 |
人類sting之小分子調節劑
|
CN111492245A
(zh)
|
2017-07-21 |
2020-08-04 |
基因泰克公司 |
癌症的治疗和诊断方法
|
EP3665197A2
(en)
|
2017-08-11 |
2020-06-17 |
H. Hoffnabb-La Roche Ag |
Anti-cd8 antibodies and uses thereof
|
EP3679040B1
(en)
|
2017-09-08 |
2022-08-03 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
EP3679159A1
(en)
|
2017-09-08 |
2020-07-15 |
H. Hoffnabb-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
KR20200100598A
(ko)
|
2017-09-26 |
2020-08-26 |
세로 테라퓨틱스, 인코포레이티드 |
키메라 포식작용 수용체 분자 및 사용 방법
|
WO2019083960A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
|
AU2018353984A1
(en)
|
2017-10-24 |
2020-05-07 |
Oncopep, Inc. |
Peptide vaccines and pembrolizumab for treating breast cancer
|
US11369608B2
(en)
|
2017-10-27 |
2022-06-28 |
University Of Virginia Patent Foundation |
Compounds and methods for regulating, limiting, or inhibiting AVIL expression
|
TW201923089A
(zh)
|
2017-11-06 |
2019-06-16 |
美商建南德克公司 |
癌症之診斷及治療方法
|
JP7254076B2
(ja)
|
2017-11-19 |
2023-04-07 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッド |
置換ヘテロアリール化合物及び使用方法
|
WO2019126136A2
(en)
*
|
2017-12-18 |
2019-06-27 |
Sterngreene, Inc. |
Pyrimidine compounds useful as tyrosine kinase inhibitors
|
JP7021356B2
(ja)
|
2017-12-21 |
2022-02-16 |
ヘフェイ インスティテューツ オブ フィジカル サイエンス, チャイニーズ アカデミー オブ サイエンシーズ |
ピリミジン誘導体系キナーゼ阻害剤類
|
AU2019209960B2
(en)
|
2018-01-20 |
2023-11-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
WO2019165434A1
(en)
|
2018-02-26 |
2019-08-29 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
AU2019243153A1
(en)
|
2018-03-28 |
2020-10-01 |
Cero Therapeutics, Inc. |
Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
|
US20210087251A1
(en)
|
2018-03-28 |
2021-03-25 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
US20210023135A1
(en)
|
2018-03-28 |
2021-01-28 |
Cero Therapeutics, Inc. |
Cellular immunotherapy compositions and uses thereof
|
WO2019213526A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
EP3788038B1
(en)
|
2018-05-04 |
2023-10-11 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
AU2019265822B2
(en)
|
2018-05-10 |
2024-07-18 |
Amgen Inc. |
KRAS G12C inhibitors for the treatment of cancer
|
AU2019275404A1
(en)
|
2018-05-21 |
2020-12-03 |
Bruker Spatial Biology, Inc. |
Molecular gene signatures and methods of using same
|
AU2019278998B2
(en)
|
2018-06-01 |
2023-11-09 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
MA52780A
(fr)
|
2018-06-11 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
JP7369719B2
(ja)
|
2018-06-12 |
2023-10-26 |
アムジエン・インコーポレーテツド |
KRas G12C阻害剤及びそれを使用する方法
|
JP7483193B2
(ja)
|
2018-06-13 |
2024-05-15 |
カリフォルニア・インスティテュート・オブ・テクノロジー |
血脳バリアを越えるためのナノ粒子とそれを用いた治療法
|
KR20210024550A
(ko)
|
2018-06-23 |
2021-03-05 |
제넨테크, 인크. |
Pd-1 축 결합 길항제, 백금 제제, 및 토포이소머라제 ii 억제제를 이용한 폐암 치료 방법
|
CN112839644A
(zh)
|
2018-07-18 |
2021-05-25 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂、抗代谢物和铂剂治疗肺癌的方法
|
WO2020023628A1
(en)
|
2018-07-24 |
2020-01-30 |
Hygia Pharmaceuticals, Llc |
Compounds, derivatives, and analogs for cancer
|
CN112805267B
(zh)
|
2018-09-03 |
2024-03-08 |
豪夫迈·罗氏有限公司 |
用作tead调节剂的甲酰胺和磺酰胺衍生物
|
JP2022500430A
(ja)
*
|
2018-09-13 |
2022-01-04 |
ユニバーシティ オブ サザン カリフォルニア |
治療薬としての、グアノシン一リン酸合成酵素の新規阻害剤
|
AU2019342099A1
(en)
|
2018-09-19 |
2021-04-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
CA3111809A1
(en)
|
2018-09-21 |
2020-03-26 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
CA3115038A1
(en)
|
2018-10-04 |
2020-04-09 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Egfr inhibitors for treating keratodermas
|
JP2022512744A
(ja)
|
2018-10-18 |
2022-02-07 |
ジェネンテック, インコーポレイテッド |
肉腫様腎臓がんのための診断および治療方法
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
MX2021005700A
(es)
|
2018-11-19 |
2021-07-07 |
Amgen Inc |
Inhibidores de kras g12c y metodos de uso de los mismos.
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
CN113490666A
(zh)
|
2018-12-19 |
2021-10-08 |
奥瑞生物药品公司 |
作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物
|
EP3898615A1
(en)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
|
MA54550A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Inhibiteurs de kif18a
|
CA3123227A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
EP3898592A1
(en)
|
2018-12-20 |
2021-10-27 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
MA54543A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Inhibiteurs de kif18a
|
EP3921443A1
(en)
|
2019-02-08 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
CN113710706A
(zh)
|
2019-02-27 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药
|
CA3131268A1
(en)
|
2019-02-27 |
2020-09-03 |
Epiaxis Therapeutics Pty Ltd |
Methods and agents for assessing t-cell function and predicting response to therapy
|
CN113727758A
(zh)
|
2019-03-01 |
2021-11-30 |
锐新医药公司 |
双环杂环基化合物及其用途
|
US20230148450A9
(en)
|
2019-03-01 |
2023-05-11 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
CN109796415B
(zh)
*
|
2019-03-29 |
2020-10-30 |
武汉德诺美生物医药股份有限公司 |
Egfr抑制剂及其应用
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
WO2020226986A2
(en)
|
2019-05-03 |
2020-11-12 |
Genentech, Inc. |
Methods of treating cancer with an anti-pd-l1 antibody
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
CA3140392A1
(en)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Solid state forms
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
CA3147276A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
MX2022001181A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
CA3146693A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CN114401953A
(zh)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
Kif18a抑制剂
|
AU2020341458A1
(en)
|
2019-09-04 |
2022-04-21 |
Genentech, Inc. |
CD8 binding agents and uses thereof
|
PE20221110A1
(es)
|
2019-09-27 |
2022-07-11 |
Genentech Inc |
Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
US20240058446A1
(en)
|
2019-10-03 |
2024-02-22 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
CN114728936A
(zh)
|
2019-10-29 |
2022-07-08 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的双功能化合物
|
CR20220240A
(es)
|
2019-11-04 |
2022-08-03 |
Revolution Medicines Inc |
Inhibidores de ras
|
MX2022005360A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
JP2022553858A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ras阻害剤
|
EP4055388A1
(en)
|
2019-11-06 |
2022-09-14 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
BR112022008858A2
(pt)
|
2019-11-08 |
2022-09-06 |
Revolution Medicines Inc |
Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
|
AU2020381458A1
(en)
|
2019-11-13 |
2022-05-12 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
JP2023501528A
(ja)
|
2019-11-14 |
2023-01-18 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の改善された合成
|
US20220395553A1
(en)
|
2019-11-14 |
2022-12-15 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
TW202132271A
(zh)
|
2019-11-14 |
2021-09-01 |
美商安進公司 |
Kras g12c抑制劑化合物之改善的合成
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
PE20221511A1
(es)
|
2019-12-13 |
2022-10-04 |
Genentech Inc |
Anticuerpos anti-ly6g6d y metodos de uso
|
WO2021127404A1
(en)
|
2019-12-20 |
2021-06-24 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
KR20220124768A
(ko)
|
2020-01-07 |
2022-09-14 |
레볼루션 메디슨즈, 인크. |
Shp2 억제제 투여 및 암 치료방법
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
MX2022009170A
(es)
|
2020-01-27 |
2022-08-17 |
Genentech Inc |
Procedimientos para el tratamiento del cancer con un anticuerpo antagonista anti-tigit.
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
WO2021233534A1
(en)
|
2020-05-20 |
2021-11-25 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
WO2021185844A1
(en)
|
2020-03-16 |
2021-09-23 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
CN115885050A
(zh)
|
2020-04-28 |
2023-03-31 |
基因泰克公司 |
用于非小细胞肺癌免疫疗法的方法和组合物
|
CN111499583B
(zh)
*
|
2020-05-22 |
2022-02-15 |
沈阳工业大学 |
喹唑啉衍生物及其作为抗肿瘤药物的应用
|
MX2022015877A
(es)
|
2020-06-16 |
2023-01-24 |
Genentech Inc |
Metodos y composiciones para tratar cancer de mama triple negativo.
|
AU2021293507A1
(en)
|
2020-06-18 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists
|
KR20230042600A
(ko)
|
2020-06-18 |
2023-03-28 |
레볼루션 메디슨즈, 인크. |
Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
EP4189121A1
(en)
|
2020-08-03 |
2023-06-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
US20230285576A1
(en)
|
2020-08-05 |
2023-09-14 |
Ellipses Pharma Ltd |
Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
|
WO2022036146A1
(en)
|
2020-08-12 |
2022-02-17 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
US11999964B2
(en)
|
2020-08-28 |
2024-06-04 |
California Institute Of Technology |
Synthetic mammalian signaling circuits for robust cell population control
|
KR20230081726A
(ko)
|
2020-09-03 |
2023-06-07 |
레볼루션 메디슨즈, 인크. |
Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
|
JP2023541916A
(ja)
|
2020-09-15 |
2023-10-04 |
レボリューション メディシンズ インコーポレイテッド |
がんの治療における、ras阻害剤としてのインドール誘導体
|
MX2023003338A
(es)
|
2020-09-23 |
2023-06-14 |
Erasca Inc |
Piridonas y pirimidonas tricíclicas.
|
MX2023003756A
(es)
|
2020-10-05 |
2023-04-24 |
Genentech Inc |
Dosis para el tratamiento con anticuerpos biespecificos anti-fcrh5/anti-cd3.
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
WO2022133345A1
(en)
|
2020-12-18 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
CA3203111A1
(en)
|
2020-12-22 |
2022-06-30 |
Kailiang Wang |
Sos1 inhibitors and uses thereof
|
KR20230146052A
(ko)
|
2021-02-12 |
2023-10-18 |
에프. 호프만-라 로슈 아게 |
암 치료용 비시클릭 테트라히드로아제핀 유도체
|
CN117203223A
(zh)
|
2021-02-26 |
2023-12-08 |
凯洛尼亚疗法有限公司 |
淋巴细胞靶向慢病毒载体
|
PE20240089A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cancer
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
EP4334321A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Ras inhibitors
|
CA3221390A1
(en)
|
2021-05-25 |
2022-12-01 |
Erasca, Inc. |
Sulfur-containing heteroaromatic tricyclic kras inhibitors
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
EP4376874A1
(en)
|
2021-07-28 |
2024-06-05 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
TW202321261A
(zh)
|
2021-08-10 |
2023-06-01 |
美商伊瑞斯卡公司 |
選擇性kras抑制劑
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
US20230202984A1
(en)
|
2021-11-24 |
2023-06-29 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
US20230203062A1
(en)
|
2021-11-24 |
2023-06-29 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
WO2024085242A2
(en)
|
2022-10-21 |
2024-04-25 |
Kawasaki Institute Of Industrial Promotion |
Non-fouling or super stealth vesicle
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|